Core Viewpoint - Yiming Anke-B (01541) has seen a significant stock price increase following the approval from the National Medical Products Administration of China for clinical trials of IMM01 (Tadapaxip) for atherosclerosis treatment [1] Group 1: Company Developments - Yiming Anke has received approval for clinical trials of IMM01 (Tadapaxip) for treating atherosclerosis, holding global intellectual property and commercialization rights for this drug [1] - The company possesses a patent family for IMM01, with authorized patents in China, the United States, Japan, and the European Union [1] Group 2: Market Analysis - Guoyuan International's report indicates that the company has regained global rights for IMM2510 and IMM27M, which will accelerate the pace of global development [1] - Clinical data for IMM2510 is reported to be excellent, with good safety and significant differentiation advantages [1] - The company is recognized as a global innovator in CD47 fusion proteins, with a rich pipeline and promising applications in oncology, autoimmune diseases, and cardiovascular fields [1] - The current market capitalization is only 2.7 billion HKD, indicating a significant undervaluation, and the company is recommended for active monitoring [1]
港股异动 | 宜明昂科-B(01541)早盘涨超10% IMM01获批进行动脉粥样硬化治疗的临床试验